Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Akron, OH
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Akron, OH
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Cincinnati, OH
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Toledo, OH
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Toledo, OH
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Oklahoma City, OK
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis
mi
from
Portland, OR
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis
mi
from
Portland, OR
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Hershey, PA
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Philadelphia, PA
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigational Site
mi
from
Charleston, SC
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigational Site
mi
from
Austin, TX
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative site
mi
from
Dallas, TX
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Tyler, TX
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Tyler, TX
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Salt Lake City, UT
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Richmond, VA
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Tacoma, WA
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated:  5/22/2014
Novartis Investigative Site
mi
from
Mobile, AL
Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis
Status: Enrolling
Updated: 5/22/2014
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Vitamin D in Ventilated ICU Patients
High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure
Status: Enrolling
Updated:  6/2/2014
Emory University Hospital
mi
from
Atlanta, GA
Vitamin D in Ventilated ICU Patients
High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure
Status: Enrolling
Updated: 6/2/2014
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vitamin D in Ventilated ICU Patients
High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure
Status: Enrolling
Updated:  6/2/2014
Emory University Hospital Midtown
mi
from
Atlanta, GA
Vitamin D in Ventilated ICU Patients
High-Dose Vitamin D and Antimicrobial Peptide Expression in Lung Failure
Status: Enrolling
Updated: 6/2/2014
Emory University Hospital Midtown
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation
Pilot Study of Optiflow as a NIV Rest Therapy
Status: Enrolling
Updated:  6/4/2014
Intensive Care Unit and Intermediate Care Unit, Tufts Medical Center
mi
from
Boston, MA
Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation
Pilot Study of Optiflow as a NIV Rest Therapy
Status: Enrolling
Updated: 6/4/2014
Intensive Care Unit and Intermediate Care Unit, Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation
Pilot Study of Optiflow as a NIV Rest Therapy
Status: Enrolling
Updated:  6/4/2014
Intensive Care Unit, Winchester Hospital
mi
from
Winchester, MA
Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation
Pilot Study of Optiflow as a NIV Rest Therapy
Status: Enrolling
Updated: 6/4/2014
Intensive Care Unit, Winchester Hospital
mi
from
Winchester, MA
Click here to add this to my saved trials
Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study
Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study
Status: Enrolling
Updated:  6/11/2014
Massachusetts General Hospital
mi
from
Boston, MA
Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study
Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study
Status: Enrolling
Updated: 6/11/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
Status: Enrolling
Updated:  7/22/2014
University of Miami Miller School of Medicine
mi
from
Miami, FL
A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
Status: Enrolling
Updated: 7/22/2014
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit
Randomized Controlled Trial of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit
Status: Enrolling
Updated:  8/13/2014
Rush University Medical Center
mi
from
Chicago, IL
RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit
Randomized Controlled Trial of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit
Status: Enrolling
Updated: 8/13/2014
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Advanced Pharma CR, LLC
mi
from
Miami, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Advanced Pharma CR, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Elite Research Institute
mi
from
Miami, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Elite Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Compass Research LLC
mi
from
Orlando, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
University at Buffalo CTRC
mi
from
Buffalo, NY
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
University at Buffalo CTRC
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Volunteer Research Group
mi
from
Knoxville, TN
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Volunteer Research Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
Idiopathic Pulmonary Fibrosis Registry for Future Studies
Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  8/21/2014
Ohio State University
mi
from
Columbus, OH
Idiopathic Pulmonary Fibrosis Registry for Future Studies
Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 8/21/2014
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Torrance, CA
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Torrance, CA
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Waterbury, CT
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Savannah, GA
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Savannah, GA
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Normal, IL
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Normal, IL
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Missoula, MT
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Missoula, MT
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Cincinnati, OH
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Columbus, OH
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Spartanburg, SC
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Long Beach, CA
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Detroit, MI
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Morristown, NJ
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Morristown, NJ
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis
mi
from
New York, NY
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis
mi
from
Pittsburgh, PA
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated:  8/29/2014
Novartis Investigative Site
mi
from
Nashville, TN
Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of P. Aeruginosa in Cystic Fibrosis Subjects Aged From 3 Months to Less Than 7 Years
Status: Enrolling
Updated: 8/29/2014
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea (The BREATHE Study)
Motivating Adherence to CPAP in Obstructive Sleep Apnea
Status: Enrolling
Updated:  9/24/2014
National Jewish Medical and Research Center
mi
from
Denver, CO
Evaluating Behavioral Treatments to Improve Adherence to Continuous Positive Airway Pressure (CPAP) Therapy in People With Obstructive Sleep Apnea (The BREATHE Study)
Motivating Adherence to CPAP in Obstructive Sleep Apnea
Status: Enrolling
Updated: 9/24/2014
National Jewish Medical and Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis.
Status: Enrolling
Updated:  9/25/2014
Nemours Children's Clinic
mi
from
Jacksonville, FL
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis
Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis.
Status: Enrolling
Updated: 9/25/2014
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated:  10/3/2014
Novartis Investigative Site
mi
from
Phoenix, AZ
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated: 10/3/2014
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated:  10/3/2014
Novartis Investigative Site
mi
from
Little Rock, AR
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated: 10/3/2014
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated:  10/3/2014
Novartis Investigative Site
mi
from
Long Beach, CA
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated: 10/3/2014
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated:  10/3/2014
Novartis Investigative site
mi
from
Los Angeles, CA
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated: 10/3/2014
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated:  10/3/2014
Novartis Investigative Site
mi
from
Ventura, CA
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules
Status: Enrolling
Updated: 10/3/2014
Novartis Investigative Site
mi
from
Ventura, CA
Click here to add this to my saved trials